To this end, studies using next generation small molecule inhibitors of CXCR1/CXCR2 and other targeted strategies, such as TNF-α therapeutics or novel inhibitors of neutrophil influx or activation, represent critical next steps toward preventing A-T lung disease. Here, CXCR1 is linked to lung disorder.